NASDAQ · HUMA
Humacyte, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for HUMA: Nov 11, 2026
Humacyte, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.09. The reported EPS for the same quarter last year was $-0.14.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.09 | $-0.08 | $-0.10 | 2 |
| Dec 2026 | $-0.09 | $-0.07 | $-0.11 | 2 |
| Mar 2027 | $-0.08 | $-0.06 | $-0.09 | 2 |
| Jun 2027 | $-0.08 | $-0.06 | $-0.09 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel · The Motley Fool- RTTNews · Oct 23, 1:15 PM EDTHumacyte's ATEV Shows Phase 3 Benefits In Women, Supports Planned FDA Label Expansion(RTTNews) – Humacyte, Inc. (HUMA) announced positive interim results from the Phase 3 V012 trial evaluating its investigational acellular tissue engineered vessel (ATEV) against arteriovenous (AV) fistula for hemodialysis access in female patients with end-stage kidney disease.
- Zacks · Oct 21, 5:00 PM EDTWhy Humacyte, Inc. (HUMA) Outpaced the Stock Market TodayHumacyte, Inc. (HUMA) closed at $0.41 in the latest trading session, marking a +1.28% move from the prior day.
- Zacks · Oct 19, 5:15 PM EDTHumacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to NoteIn the most recent trading session, Humacyte, Inc. (HUMA) closed at $0.4, indicating a -6.5% shift from the previous trading day.
- Zacks · Oct 13, 5:15 PM EDTHumacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to KnowHumacyte, Inc. (HUMA) concluded the recent trading session at $0.36, signifying a -7.88% move from its prior day's close.
- Fintel · Oct 7, 2:22 PM EDTBarclays Initiates Coverage of Humacyte at Equal-WeightFintel reports that on October 7, 2026, Barclays initiated coverage of Humacyte (NASDAQGS:HUMA) with a Equal-Weight recommendation. This initiation follows a prior action on April 8, 2026, when Barclays maintained an Overweight rating on the stock. Prior to the current rating act
- Zacks · Oct 6, 5:00 PM EDTHumacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You TradeHumacyte, Inc. (HUMA) concluded the recent trading session at $0.48, signifying a -4.26% move from its prior day's close.
- Zacks · Sep 25, 5:00 PM EDTHumacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's WhyThe latest trading day saw Humacyte, Inc. (HUMA) settling at $0.56, representing a -2% change from its previous close.
- Zacks · Sep 18, 6:00 PM EDTHumacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to KnowHumacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.
- Zacks · Sep 17, 9:30 AM EDTIs Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
- RTTNews · Sep 9, 10:52 AM EDTHumacyte's Symvess Shelf Life Extended To 36 Months Following FDA Authorization(RTTNews) – Humacyte Inc. (HUMA), announced that the U.S. FDA has authorized an extension of the expiration dating period for Symvess, its acellular tissue-engineered vessel (ATEV), from 18 months to 36 months when stored under approved refrigerated conditions.
- RTTNews · Aug 21, 10:17 AM EDTWeekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks(RTTNews) – This week's global biopharma roundup captured a mix of regulatory approvals, strategic partnerships, acquisitions, and merger activity, alongside clinical trial breakthroughs and halts. Positive readouts across autoimmune myositis, glioma, and melanoma were offset by
- The Motley Fool · Aug 19, 10:13 AM EDTHumacyte (HUMA) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Humacyte, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.